Progress in prostate cancer chemoprevention: Modulators of promotion and progression

Urology

Volumn 58, Issue 6, 2001, Pages 835-842

  Lieberman, Ronald ^a   Bermejo, Carlos ^b   Akaza, Hideyuki ^c   Greenwald, Peter ^a   Fair, William ^d   Thompson, Ian ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALITRETINOIN; ALPHA TOCOPHEROL; BICALUTAMIDE; CELECOXIB; DAIDZEIN; DITHIOL DERIVATIVE; EFLORNITHINE; FINASTERIDE; FLURBIPROFEN; FLUTAMIDE; GENISTEIN; GONADORELIN; LEFLUNOMIDE; LONAFARNIB; NILUTAMIDE; PERILLYL ALCOHOL; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM; SEMAXANIB; SOYBEAN PROTEIN; SULINDAC SULFONE; TAMOXIFEN; TOREMIFENE; TROGLITAZONE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DRUG INDUSTRY; FACTORIAL ANALYSIS; FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; MELANOMA; POPULATION RESEARCH; PRECURSOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; REVIEW; SMOKING; TEA; TREATMENT OUTCOME;

ALKYL AND ARYL TRANSFERASES; ANDROGEN ANTAGONISTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; HUMANS; MALE; MICRONUTRIENTS; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SOYBEAN PROTEINS; STEROIDS; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 0035667260     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01416-9     Document Type: Review

References (29)

1. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients
2. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
3. Development of new cancer chemoprevention agents: Role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
4. Strategies for chemoprevention of prostate cancer
5. New opportunities for uncovering the molecular basis of cancer
6. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland
7. Design of the Prostate Cancer Prevention Trial (PCPT)
8. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats
9. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer
10. Cloning of a novel receptor expressed in rat prostate and ovary
11. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial
12. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial
13. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer
14. Intake of carotenoids and retinol in relation to risk of prostate cancer
15. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom
16. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin
17. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats
18. Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice
19. Is vitamin D deficiency a risk factor for prostate cancer (hypothesis)?
20. 1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells
21. Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women
22. Drug development in prostate cancer
23. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
24. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation
25. Surrogate endpoints in clinical trials: Definition and operational criteria
26. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate endpoints for clinical trials
27. Expression profiling using cDNA microarrays
28. 3) spatial resolution
29. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials